Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Bevacizumab
Bevacizumabum
Bleomycin Sulphate
Carboplatin
Chlorambucilum
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Docetaxelum
Doxorubicinum
Doxorubicinum Liposomanum Pegylatum
Epirubicinum
Etoposidum
Fluorouracilum
Gemcitabine
Ifosfamidum
Irinotecanum
Melphalanum
Methotrexatum
Paclitaxel
Tamoxifenum
Topotecanum Inj.
Trabectedin
Trastuzumabum I.v.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- ovarian cancer
- endometrial cancer
- » Assessment of the Concentrations of Functional Proteins as Potential Early Markers of Insulin Resistance in Women With Polycystic Ovary Syndrome
- » A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
- » Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
- » A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
- » FRAmework-01: A Two-Part Phase 3 Study of LY4170156 Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
